MedPath

Comparison between intravesical BCG therapy and intravesical BCG and MMC therapy for prevention of recurence and treatment of in situ cancer in non-muscle invasive bladder cancer patients with intermediate or high risk disease.

Not Applicable
Conditions
Bladder cancer
Registration Number
JPRN-UMIN000024162
Lead Sponsor
agasaki University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
284
Inclusion Criteria

Not provided

Exclusion Criteria

1: The chance of living over 6 months 2: With active tuberculosis 3: Allergy for BCG or MMC 4: With other maligancy or has plan of treatment for the disease. 5: The doctor judged as improper.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath